FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, is reporting on its annual general meeting of shareholders; the meeting was held online on June 23, 2022. During the meeting, seven nominees were elected as directors of the company. The new directors are Anthony Durkacz, Zeeshan Saeed, Donal Carroll, Adnan Bashir, Fernando Cugliari, Nitin Kaushal and Lawrence Latowsky; the directors will serve until the next annual meeting of shareholders or until successors are elected or appointed. During the meeting, shareholders also reappointed MNP LLP as the company auditor and authorized company directors to fix the auditor’s remuneration. The report also included corporate updates, including notice that FSD Pharma remains active with its share repurchase program, which was initiated on Dec. 30, 2021. In addition, the report noted that individuals qualified as “insiders” by regulatory standards, which includes FSD Pharma cofounder and interim CEO Anthony Durkacz, FSD Pharma cofounder and president Zeeshan Saeed and director Donal Carroll continue to purchase shares of HUGE in the open market. The company also had an active presence at BIO-2022 and “has participated in numerous meetings, establishing new inroads for potential collaborations and partnerships as an ongoing effort to strengthen FSD’s current pipelines and global market access strategies,” the report noted.
To view the full press release, visit https://nnw.fm/kIL7j
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultramicronized palmitoyl ethylamine (“PEA”) or FSD-PEA, formerly called FSD-201. Lucid Psycheceuticals Inc. is a wholly owned subsidiary focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information about the company, please visit www.FSDPharma.com.
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
NetworkNewsWire is part of the InvestorBrandNetwork